外周动脉疾病患者的吸烟行为与主要心脑血管及肢体事件
与维持吸烟组相比,戒烟组主要不良心脑血管事件风险显著降低(HR 0.88,95%CI 0.84-0.91),主要不良肢体事件风险也显著降低(HR 0.83,95%CI 0.73-0.94);减烟组则无显著差异。剂量反应分析显示仅接近完全戒烟才有风险降低,心肌梗死亚组获益最大。结论支持将完全戒烟作为外周动脉疾病患者的主要治疗目标。
要点
- 在新诊断外周动脉疾病的活动吸烟者中,完全戒烟与主要不良心脑血管事件风险降低相关(HR 0.88,95%CI 0.84-0.91)。
- 完全戒烟同时与主要不良肢体事件风险降低相关(HR 0.83,95%CI 0.73-0.94),包括肢体血运重建或大截肢。
- 部分减烟(每日吸烟量减少≥20%)与主要不良心脑血管事件(HR 1.00,95%CI 0.96-1.04)和主要不良肢体事件(HR 0.92,95%CI 0.81-1.04)均无显著关联。
- 剂量反应分析显示风险降低仅见于接近完全戒烟,各亚组结果一致,心肌梗死获益最大。
- 研究支持将完全戒烟而非减烟作为外周动脉疾病患者的主要治疗目标。
适用人群与场景
- 纳入者平均年龄54.2岁(SD 11.8),88.5%为男性。
- 排除标准原文未提及。
诊断标准与关键阈值
- 戒烟者:诊断后完全停止吸烟。
- 减烟者:诊断后每日吸烟量减少≥20%。
- 维持吸烟者:每日吸烟量减少<20%或任何增加(参照组)。
处置流程与药物剂量
- 原文未提及具体戒烟干预措施或药物剂量。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:全国性、基于人群的回顾性队列研究,数据来自韩国国民健康保险服务-国家健康信息数据库。
- 人群:40岁及以上、新诊断外周动脉疾病、诊断前主动吸烟且诊断前后完成健康检查者,随访至2021年。
- 主要终点:主要不良心脑血管事件(全因死亡、心肌梗死、冠状动脉血运重建、缺血性卒中)和主要不良肢体事件(肢体血运重建或大截肢)。
- 与维持吸烟组相比,戒烟组主要不良心脑血管事件发生率17.8 vs 20.2/1000人年,HR 0.88(95%CI 0.84-0.91);主要不良肢体事件发生率1.4 vs 1.8/1000人年,HR 0.83(95%CI 0.73-0.94)。
- 减烟组主要不良心脑血管事件HR 1.00(95%CI 0.96-1.04),主要不良肢体事件HR 0.92(95%CI 0.81-1.04),均无显著差异。
- 剂量反应分析显示风险降低仅见于接近完全戒烟;各亚组结果一致,心肌梗死获益最大。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 证据等级或推荐强度:原文未提及。
- 局限:回顾性设计;仅纳入诊断前后均完成健康检查者;吸烟行为依赖自我报告;数据来自韩国单一国家数据库;原文未提及其他局限。
对床旁实践的改变
- 对新诊断外周动脉疾病的活动吸烟者,应明确建议完全戒烟而非仅减少吸烟量,因完全戒烟与主要不良心脑血管事件和主要不良肢体事件风险降低相关,而部分减烟无显著获益。
- 减烟不能作为替代目标,剂量反应分析显示仅接近完全戒烟才有风险降低。
- 本研究为观察性队列,不能确立因果关系;适用人群为40岁及以上、新诊断外周动脉疾病且诊断前主动吸烟者,不适用于非吸烟者或未完成健康检查者。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Smoking is the strongest modifiable risk factor for peripheral arterial disease (PAD), yet evidence on how postdiagnosis smoking behavior changes affect clinical outcomes remains limited.
OBJECTIVE: To evaluate the association among smoking cessation, reduction, and continuation after PAD diagnosis and subsequent cardiovascular and limb-specific outcomes.
DESIGN, SETTING, AND PARTICIPANTS: This nationwide, population-based, retrospective cohort study assessed adults 40 years or older newly diagnosed with PAD from January 1, 2011, to December 31, 2018, with follow-up through 2021, who reported active smoking before diagnosis and completed health examinations before and after diagnosis. Data were from the Korean National Health Insurance Service-National Health Information Database. Data analysis was conducted from December 2023 to November 2025.
EXPOSURES: Postdiagnosis smoking behavior, classified as quitters (complete cessation), reducers (≥20% decrease in daily cigarette consumption), or maintainers (<20% decrease or any increase in consumption [reference group]).
MAIN OUTCOMES AND MEASURES: Main outcomes were major adverse cardiovascular and cerebrovascular events (MACCEs), including all-cause death, myocardial infarction, coronary revascularization, and ischemic stroke, and major adverse limb events (MALEs), including limb revascularization or major amputation. Inverse probability of treatment-weighted hazard ratios (HRs) were estimated using Cox proportional hazards regression models for MACCEs and Fine-Gray competing risk models for MALEs.
RESULTS: Among 189 545 active smokers with incident PAD (mean [SD] age, 54.2 [11.8] years; 167 659 [88.5%] male), 38 952 (20.6%) quit smoking, 38 709 (20.4%) reduced consumption, and 111 884 (59.0%) maintained smoking. Compared with maintainers, quitters had significantly lower risks of MACCEs (17.8 vs 20.2 per 1000 person-years; HR, 0.88; 95% CI, 0.84-0.91) and MALEs (1.4 vs 1.8 per 1000 person-years; HR, 0.83; 95% CI, 0.73-0.94). Reducers showed no significant difference in MACCEs (HR, 1.00; 95% CI, 0.96-1.04) or MALEs (HR, 0.92; 95% CI, 0.81-1.04). Dose-response analysis showed risk reduction only with near-complete cessation. Findings were consistent across subgroups, with the largest reductions observed for myocardial infarction.
CONCLUSIONS AND RELEVANCE: In this cohort study of 189 545 active smokers with newly diagnosed PAD, complete smoking cessation was associated with lower risks of both cardiovascular and limb-specific adverse events, whereas partial smoking reduction showed no significant benefit. These findings support complete cessation as the primary therapeutic target in patients with PAD.
参考来源
- Kim HK, Kim MS, Ahn S, et al. Smoking Behavior and Major Cardiovascular and Limb Events in Patients With Peripheral Artery Disease. JAMA Netw Open. 2026. PMID: 42616502. doi:10.1001/jamanetworkopen.2026.29337
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。